Standout Papers

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced N... 2013 2026 2017 2021 367
  1. Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer (2013)
    David R. Spigel, Thomas J. Ervin et al. Journal of Clinical Oncology

Immediate Impact

1 by Nobel laureates 1 from Science/Nature 64 standout
Sub-graph 1 of 22

Citing Papers

Multidrug-resistant Gram-negative bacterial infections
2025 Standout
Bacteriophage therapy for multidrug-resistant infections: current technologies and therapeutic approaches
2025 Standout
4 intermediate papers

Works of B. Godbert being referenced

Effectiveness of bacteriophages in the sputum of cystic fibrosis patients
2014

Author Peers

Author Last Decade Papers Cites
B. Godbert 315 48 201 149 17 532
Samir Wadhawan 90 88 176 187 11 462
Huabang Zhou 138 91 233 79 20 585
Xiaoli Chai 151 88 333 300 10 571
Guangfa Zhao 144 34 133 112 20 511
Roxana Zaharie 115 125 125 78 27 604
Bo Young Ahn 54 135 161 80 23 632
Kazuhiro Satonaka 82 52 231 41 19 470
Iman Gouda 96 52 92 34 23 572
Junji Shibata 63 137 73 262 22 571
Kate Poropatich 154 67 154 16 16 587

All Works

Loading papers...

Rankless by CCL
2026